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Background: Chronic low back pain affects daily activities at home and workplaces and causes a huge
economic burden. Current therapeutic options are very limited and the effects of available pharmaco-
logical agents are less than satisfactory. While NSAIDs might be effective for the short term and opioids
might help with urgent pain relief and improving the life quality, their long-term use is associated with
signiﬁcant side effects and drug misuse or abuse. To seek alternative pharmacological agents for effective
treatment, we examined the therapeutic potential of the extracts of Vaccinia variola-inoculated rabbit
skin (Analgecine, abbreviated as AGC) in patients with chronic low back pain due to degenerative
vertebral disorders.
Methods: In this randomized multi-center double-blind placebo-controlled phase 3 clinical trial (Chinese
Clinical Trial Registry number 2009L01498), we enrolled patients (aged 26e70 years) with chronic low
back pain for at least 3 months due to degenerative spinal (vertebral) disorders from 7 medical centers in
China, and randomly allocated 459 participants to receive oral AGC or placebo for 28 days to study the
efﬁcacy and safety of AGC. Randomization was performed according to a centralized randomization
schedule, which was blocked by study sites and generated by an unmasked statistician independent of
study conduct and data analysis. Both participants and staff at each study site were masked to treatment
assignment. The primary efﬁcacy endpoint was the change of the mean pain intensity, based on an 11-
point numerical rating scale, between the baseline and the last week of treatment, with the primary
efﬁcacy analysis of intention to treat. The ratio between exposed and unexposed groups was designed to
be 3:1 in order to increase the likelihood of demonstrating the AGC effect upon repeated measures.
Results: 347 patients were assigned to receive AGC (4 units/tablet; 2 tablets twice a day) and 112 patients
were to take placebo. Among them, 324 patients taking AGC and 112 receiving placebo completed the
assessment. Patients receiving AGC reported signiﬁcant pain relief at the end of week 2 and 3 comparedine, Kaohsiung Medical Uni-
Dong), stevelin@kmu.edu.tw
Inc. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
J. Dong et al. / Contemporary Clinical Trials Communications 2 (2016) 16e24 17to those taking placebo, with mean reduction of the pain scores as 1.7 vs. 0.9 at week 2 (p < 0.0001) and
2.8 vs. 1.2 at week 3 (p < 0.0001). A total of 47 AGC-treated patients reported 85 treatment emergent
adverse events while 16 patients taking placebo reported 26 events, but no serious side effects were
found to be related to AGC treatment.
Conclusion: Analgecine (AGC, 8 units twice daily) effectively alleviates chronic low back pain due to
degenerative vertebral disorders when compared to placebo and is well tolerated by tested individuals,
and can be considered as a ﬁrst-line treatment for chronic low pain due to degenerative vertebral
diseases.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Lower back pain (LBP) is one of the most common reasons for
physician consultation in developed countries [1]. Once LBP per-
sists on most days in a 3-month period, it becomes chronic LBP
(cLBP) and has detrimental effects over the life quality. Unfortu-
nately, only one-third of LBP patients recover within the ﬁrst 3
months and 65% of them still suffer from pain one year after onset
[2]. Most cases of cLBP result from mechanical (degenerative) fac-
tors, e.g., lumbar spondylosis, degeneration of intervertebral discs
or facet joints, or spondylolisthesis etc.. The cLBP may also result
from non-mechanical factors or systemic diseases, including neo-
plasms, infection, inﬂammatory, vascular or metabolic disorders. In
terms of treatment, prescription of drugs is the ﬁrst step to reduce
the pain intensity, thereby facilitating the implementation of
behavior changes and exercise. However, current treatment regi-
mens are less than satisfactory and the choice for appropriate
pharmaceutical agents can be confusing. For example, paracetamol
is often recommended as the ﬁrst-line therapy in many guidelines
[3,4], but a recent meta-analysis has concluded with its ineffec-
tiveness [5]. Evidences exist for the efﬁcacy of NSAIDs; neverthe-
less, the long-term effect remains uncertain and the safety proﬁle
casts concerns over the prolonged use because of adverse effects
[6e10], which increase in the incidence along with the age and
dose [10,11]. Opioid drugs, including Tramadol, have also been
legitimately used on cLBP and are indeed effective, at least for the
short term [3,12e14]. Consequently, they have been increasing
prescribed [15] but the long-term use is accompanied by risks for
comorbidity, substance abuse and side effects. It has also been
estimated that up to 40% of pain patients on chronic opioid therapy
display aberrant drug-related behaviors [16] and this number is
rising because the prevalence of chronic pain is increasing due to
population aging [17]. Hence, US FDA has urged for developing high
potency opioid (or alternatives) to address the risks of abuse,
misuse, and the exposure of persons who are not opioid-tolerant
[18]. The clinical efﬁcacy of antidepressants and anticonvulsants
has not been well established, at least when used as monotherapy
[3,19], and a recent meta-analysis has invalidated the effect of an-
tidepressants for cLBP [20]. Given the rates of disability from cLBP
increase, it is imperative to respond to the growing disease burden
by devising effective strategies and drugs.
In addition to the current pain killers in the west, a biological
mixture trademarked as Analgecine (abbreviated as “AGC”; Van-
world Pharmaceuticals Ltd., China) has been clinically used in China
as an analgesic. It is manufactured from the extracts of rabbit
(Oryctolagus cuniculus of the Leporidae family) skin that has been
inﬂamed by inoculation of Vaccinia variola. Despite the active
ingredient remains to be characterized, small-scaled clinical trials
have established the effectiveness against various somatic pain and
neuropathic pain, [21,22] and importantly, no serious side effects
have been reported. Its effect against chronic low back pain has not
been examined by a well-designed randomized trial. In this study,we assessed the analgesic efﬁcacy and safety of AGC for the treat-
ment of cLBP in patients recruited from 7 medical centers in China.
2. Methods
2.1. Study design and participants
The study was a multi-center, double-blind, placebo-controlled,
parallel-group, randomized phase III clinical trial (Chinese Clinical
Trial Registry number 2009L01498). The study duration was
designed to be 8 weeks, including a screening (wash-out) period
(14 days), a treatment period (28 days), and a follow-up period (14
days). Participants were recruited from 7 medical centers in China:
(1) Zhongshan Hospital of the Shanghai Fudan University, (2) the
6th People's Hospital of the Shanghai Jiao-Tong University, (3) the
3rd Hospital of the Hebei Medical University, Shijiazhuang, (4) the
People's Hospital of Tianjin, (5) the Union Hospital of the Huazhong
University of Science and Technology, Wuhan, (6) the Sun Yat-Sen
Memorial Hospital of the Sun Yat-Sen University, Guangzhou, and
(7) the Xijing Hospital of the 4th Military Medical University, Xian.
The trial sites included orthopedic or pain clinics in the hospitals
and clinical trial facilities. All patients had persistent chronic low
back pain for more than 3 months from degenerative spinal
(vertebral) diseases due to herniation of intervertebral discs (HIVD)
or lumbar spondylolisthesis of isthmic, degenerative or traumatic
types (conﬁrmed by CT scan or MRI, excluding causes of cancer
metastasis, metabolic factors or infection). They either had no
surgery or had surgical treatment but still suffered from pain for
more than 3 months after operation. All participants were aged
between 18 and 70 years old and were able to give written con-
sents. The pain severity was evaluated by an 11-point numerical
rating scale (NRS) with the anchor points being 0 (no pain) and
maximum being 10 (pain as bad as you can imagine) to describe
“pain on average in the last 24 h”. The baseline mean pain intensity
score was calculated from the daily pain scores collected during 5
consecutive days at the end of the screening period (i.e., prior to the
day 1 of treatment with AGC or placebo) and all participants had
NRS 3 to 8 (both ends included). Those who had a baseline NRS
varying by 2.5 points or more in any week during the screening
period were excluded to avoid adverse changes in the effect size
from enrolled patients with highly variable pain scores at baseline.
Written consents were obtained from all participants before the
study. The sample size of each group (exposed vs. non-exposed)
was calculated to be minimally 68 (see “statistical analysis”
below). Meanwhile, we increased the number of the exposed pa-
tients to maximize the possibility of observing treatment effects
and therefore designed to recruit more than 300 patients for the
exposure (treatment) group. Recruitment endedwith enrollment of
459 patients for randomization and 347 were allocated to receive
AGC treatment while 112 were to receive placebo (ratio 3:1). The
trial protocol was approved by the institutional research ethics
committee of each hospital, as well as by the China FDA. The
J. Dong et al. / Contemporary Clinical Trials Communications 2 (2016) 16e2418inclusion and exclusion criteria, and exit criteria were detailed in
the Appendix 1.
2.2. Randomization and masking
Randomization was conducted through a centralized randomi-
zation schedule, blocked by study site, to one of two treatment
groups: Analgecine (AGC) tablet twice daily or placebo. The
randomization schedulewas generated by an unmasked statistician
at the Yushi Medicinal Technology Co. Ltd (a Contract Research
Organization at Guangzhou, China), which was independent of the
study conduct and data analysis. The random allocation sequence
was implemented by sequentially numbered containers. The tab-
lets of AGC or placebo were prepared by a central pharmacy at the
InCROM Group, China, as appropriately labeled patient packs and
distributed to each clinical site. Both patients and staff at each site
were masked to treatment assignment. Study personnel respon-
sible for the operation of the study were also masked to treatment
assignment from randomization.
2.3. Procedures
After randomization, patients completed efﬁcacy endpoints,
patient-reported outcome measures and then received a treatment
pack containing either Analgecine (AGC) tablets or placebo tablets
(identical to AGC tablets). We instructed participants to take two
tablets (AGC 4 units per tablet, Appendix 2; or placebo) by mouth
twice daily (morning and evening) after a meal. We gave patients a
diary card from the ﬁrst week of treatment to record their daily
pain intensity and time of study drug administration. The diary
allowed up to 8 days of information to be recorded, for ﬂexibility in
scheduling of clinic visits. Doses were then self-administered until
the next clinic visit (day 7). On day 7, we collected the diary card
and gave patients a new diary card for the treatment of next week.
This pattern of clinic visits was continued weekly to collect the ﬁnal
pain diary entry and tertiary efﬁcacy patient-reported question-
naires completed in the evening of the scheduled last day (i.e., day
28). Patients attended their ﬁnal clinic visit on scheduled day 42 for
follow-up pain assessments. The primary efﬁcacy endpoint was the
change in the mean pain intensity between baseline and the ﬁnal
week of dosing. Secondary efﬁcacy endpoints were onset and
maintenance of effect, as deﬁned by the decrease in the mean pain
intensity throughout the entire treatment period, and the propor-
tion of patients achieving 30% or greater reductions in mean pain
intensity compared to baseline. In a post-hoc analysis, we calcu-
lated the proportion of patients achieving 50% or greater reductions
in mean pain intensity compared to baseline. The tertiary efﬁcacy
endpoint was the time to 30% decrease in mean pain intensity from
baseline. Treatment-emergent adverse events were deﬁned as
adverse events that began or worsened in severity after at least one
dose of the study drug had been administered. We analyzed the
reduction of numerical rating scale (NRS) each week and set a
stopping guideline of P < 0.001 (between exposed and un-exposed
groups) for beneﬁt on the primary endpoint for consecutive 2
weeks. For this purpose, we performed the interim analysis at the
end of each week till week 3 and in order to control the overall type
1 error under 0.05, the a spending function was chosen to be
0.001 at week 2 and 3. The blood cell counts and serum biochem-
istry were also studied at the end of the trial.
2.4. Statistical analysis
The primary efﬁcacy analysis according to the statistical analysis
plan included all randomized patients (intention-to-treat principle)
and used last observation carried forward imputation.Consequently, in a post hoc primary efﬁcacy analysis, we did
baseline observation carried forward imputation and included all
randomized patients. For the secondary endpoint of mean weekly
pain intensity, we used a mixed model repeated measures analysis
to assess the mean proﬁle over time for each treatment group. The
ﬁxed effects included in the linear model were: age, sex, treatment,
visit, and the interaction between treatment and visit. The random
effect was patient. The variance covariance structure for the mixed
model was chosen on the basis that it minimized the Akaike in-
formation criteria and the Bayesian information criteria. For mean
pain intensity over time, the unstructured variance covariance
model minimized both sets of criteria, and was therefore used for
the mixed model repeated measures analysis. Differences between
groups were analyzed with the use of mixed model repeated
measures analysis and Dunnett's multiple-comparison post hoc
test. With post-hoc sensitivity analysis, we matched the placebo
(unexposed) patients to AGC (exposed) patients by age and sex in a
ratio of 1 to 1 (112:112) based on the logit of the propensity score
using a logistic regression model. Cohen's f2, a measure of local
effect size, was calculated using a multiple mixed repeated mea-
sures model [23].
Interim analysis was conducted at the end of each week.
Furthermore, a stopping guideline was speciﬁed when signiﬁcant
statistical difference in the pain reduction was observed between
the treatment and placebo groups with P < 0.001 for consecutive 2
weeks. A responder was deﬁned as any patient who achieved a 30%
or greater (or a 50% or greater reduction in separate analysis) in the
mean pain intensity from baseline to the ﬁnal week, with last
observation carried forward for missing observations. We used
multiple logistic regression to compare the proportion of patients
responding in each treatment group with covariates of age and sex
and the pre-speciﬁed measurement of the treatment effect was the
adjusted odds ratio. We also calculated the unadjusted odds ratio.
Finally, we have reported the comparison of the proportion of pa-
tients responding in each treatment group as the unadjusted
relative risk for ease of interpretation. We estimated the distribu-
tion of the tertiary efﬁcacy endpoint of time to 30% decrease in
mean pain intensity from baseline with the KaplaneMeier method.
We used a Cox proportional hazards model with age and sex as
covariates to test the difference between the treatment groupswith
respect to the distribution of time to a 30% or greater reduction in
weeklymean pain intensity, and we established an adjusted hazard
ratio. Data handling and associations were performed using the SAS
version 9.3 (SAS Institute Inc., Cary, North Carolina, USA). We
calculated the sample size of 68 patients per group with the
assumption of a mean pain intensity (numerical rating scale) dif-
ference between the two groups of 1.00 units (SD 1.60), which
provided 95% power to detect such a differencewith a two-sample t
test with a two-sided type I error of 0.05. However, according to ICH
guidelines, we increased the sample numbers of the exposed pa-
tients and allocated randomly 347 and 112 for the treatment and
placebo group, respectively.
2.5. Role of the funding source
Data collection and some analyses reported here were done by
an independent contract research organization (Yushi Medicinal
Technology Co. Ltd), and most statistical analysis was conducted by
an independent statistician at the Kaohsiung Medical University.
Blood cell counts and serum biochemistry were analyzed at the
hospitals where the trials were conducted.
3. Results
Between Oct 2013 and July 2014, 483 patients from 7 medical
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of not meeting the inclusion criteria (n ¼ 19) or declining to
participate (n ¼ 5). Therefore, 459 participants for randomization
and 347 were allocated to receive AGC while 112 were to receive
placebo treatment. After allocation, 6 in the AGC group and 3 in the
placebo group withdrew consents. During follow-up, 17 in the AGC
group and 5 in the placebo group were excluded due to loss for
follow-up visits, acute infection or non-adherence to the speciﬁed
timeline for medication. Therefore, 324 receiving AGC and 104
receiving placebo completed the follow-up assessment (Fig. 1).
Analyzes of the participants, including 23 in the AGC group and
8 in the placebo group who were lost for follow-up, showed that
there was no difference in the personal characteristics when
comparing AGC-treated and placebo-treated patients, including
age, sex, body height or weight, habits of smoking or alcohol use.
None of the participants had concomitant treatment for their cLBP,
and no difference either in the percentage of patients receiving
treatment for existing chronic diseases (15% vs. 13.4% in AGC-
treated and placebo-treated patients for, e.g., hypertension and/or
diabetes, respectively). The proportion of participants between AGC
and placebo group contributed by any individual center did not
differ either. The baseline pain intensity was also similar between
groups (Table 1). Analyses of the primary efﬁcacy endpoint
demonstrated that the changes of the mean pain intensity (NRS)
from baseline at week 2 and 3 were signiﬁcantly higher with AGC
treatment in comparison to placebo treatment (5.4e3.7 vs. 5.4 to
4.5 at week 2, and 5.4 to 2.6 vs. 5.4 to 4.2 at week 3, Table 1), based
on last observation carried forward imputation. Consistently, the
weekly percentage of NRS reductionwas also signiﬁcantly higher in
AGC than placebo group (31.6% vs.17.1% and 54.7% vs. 23.2% at week
2 and 3 compared to the baseline, respectively; Table 2), indicating
a signiﬁcant time-dependent pain reduction for AGC, which was
also demonstrated in Fig. 2 showing the time course for change
from baseline in weekly pain intensity. Because signiﬁcant
improvement with AGC treatment was observed for consecutive 2
weeks (p < 0.0001 between AGC and placebo at both week 2 and 3,
Fig. 2), which fulﬁlled the pre-speciﬁed criterion for early termi-
nation, we stopped the trial at the end of the 3rd week. Analyses of
the secondary endpoint which was directed at the onset andFig. 1. Enrollmenmaintenance of therapeutic effects showed that a greater per-
centage of patients receiving AGC achieved 30% or greater reduction
of the pain intensity in week 3 of treatment compared to baseline
(Table 2 and Fig. 2). For the AGC-treated group, the KaplaneMeier
method estimated a median time to achieve a 30% or greater
reduction in mean pain intensity of 14 days (95% CI 14e21); how-
ever, for the placebo group the median time could not be estimated
because less than 50% of patients achieved a 30% or greater
reduction within the 21-day treatment period (Table 2 and Fig. 3).
We have also calculated the proportion of patients achieved 50%
reduction of the pain intensity, because a response rate of 50% was
often used in meta-analysis of pain research. Again, a higher per-
centage of patients receiving AGC achieved 50% or greater reduction
than the placebo group (Table 2). Calculation of the numbers
needed to be treated (NTT), i.e., the number of patients that need to
be treated for one to beneﬁt from the treatment when compared
with a control, showed that at week 3 the NTT was 2.20 and 2.15 for
30% and 50% or higher responder rates, respectively (Table 2),
implying the presence of therapeutic beneﬁts that might outweigh
the risks from potential side effects.
In terms of treatment-emergent adverse events, 47 patients
receiving AGC reported 85 treatment-emergent adverse events
(Table 3). Among 324 tested individuals, 17 (5.2%) had acute upper
airway infection complicated with acute bronchitis and/or pneu-
monia (classiﬁed as “major adverse events”) and all recovered with
no sequela. The remaining events were regarded asminor andwere
listed in Table 3. In the placebo group, 16 patients reported 26
treatment-emergent adverse events. Among the 104 placebo-
treated individuals, 6 had acute airway infection complicated
with bronchitis/pneumonia and 20 had minor events, as similarly
described to those in AGC-treated group (Table 3). Overall, no sig-
niﬁcant difference in the frequency of treatment-emergent adverse
event was noticed between two groups. Furthermore, no deﬁnite
cause-effect existed between the occurrence of any adverse event
and the treatment (data not shown). Blood cell count and serum
biochemistry at the end of the treatment showed that patients in
the AGC-treated group did not have any abnormal value in either
blood cell count or biochemical parameters (e.g., liver and renal
functions; Table 4). No abnormality was observed from the routinet outcome.
Table 1
Characteristics of the study participants.
AGC Placebo P value
n ¼ 347 n ¼ 112
Age (SD), years 50.0 (12.1) 50.7 (10.9)
Sex, n (%)
Males 124 (35.7) 45 (40.2)
Females 223 (64.3) 67 (59.8)
Height (SD), cm 164.1 (7.7) 163.3 (7.6)
Weight (SD), kg 63.8 (10.5) 63.3 (10.3)
Body mass index (SD), kg/m2 23.6 (3.2) 23.7 (3.3)
Cigarette use, n (%)
Non-smoker 282 (81.3) 90 (80.3)
Current smoker 61 (17.6) 20 (17.9)
Ever smoker 4 (1.1) 2 (1.8)
Alcohol use, n (%)
Non-drinker 305 (87.9) 94 (83.9)
Current drinker 40 (11.5) 18 (16.1)
Ever drinker 2 (0.6) 0 (0.0)
History of drug allergy, n (%)
No 331 (95.4) 102 (91.1)
Yes 16 (4.6) 10 (8.9)
Drug treatment of low back pain, other, n (%)
No 347 (100.0) 112 (100.0)
Yes 0 (0.0) 0 (0.0)
Drug treatment of chronic disease, n (%)
No 295 (85.0) 97 (86.6)
Yes 52 (15.0) 15 (13.4)
Center, n (%)
1 63 (18.2) 20 (17.9)
2 17 (4.9) 6 (5.4)
3 72 (20.8) 23 (20.5)
4 54 (15.6) 18 (16.1)
5 61 (17.6) 18 (16.1)
6 71 (20.5) 24 (21.4)
7 9 (2.6) 3 (2.7)
Numerical rating scale (SD)
Baseline 5.4 (1.3) 5.4 (1.2) 0.9390
Week 1 4.6 (1.3) 4.8 (1.3) 0.1306
Week 2 3.7 (1.4) 4.5 (1.4) <0.0001
Week 3 2.6 (1.6) 4.2 (1.6) <0.0001
Numerical rating scale change % (SD)
Week 1 vs. Baseline 13.6 (15.4) 9.8 (15.2) 0.0525
Week 2 vs. Baseline 31.6 (14.3) 17.1 (15.3) <0.0001
Week 3 vs. Baseline 54.7 (22.3) 23.2 (19.8) <0.0001
Note: SD, standard deviation; %, percentage. Data of continuous and categorical
variables were analyzed by t test or Wilcoxon rank-sum test and chi-square test or
Fisher's exact test to make comparisons between groups, as appropriate.
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group had a higher incidence of low red blood cell count (10 pa-
tients) and lower-than-normal hemoglobin values (12 patients
including the 10 with a low red blood cell count; Table 4). All these
12 patients were post-menopausewomen. No difference was noted
in white blood cell or platelet counts. Furthermore, while the
incidence for the higher-than-normal serum creatinine level was
similar between two groups, the incidence for the higher-than-
normal BUN was higher in placebo-treated than AGC-treated pa-
tients (9.6% of patients receiving placebo vs. 4% patients receiving
AGC; Table 4). The reason remains unknown but there appeared to
be no disturbance to the daily activities of these patients (infor-
mation obtained from interviews at the follow-up period). There
was also no signiﬁcant difference in the incidence of abnormal
electrocardiography readings (e.g., arrhythmias, inverted T waves,
prolonged PR or QT intervals) between 2 groups (Table 4).
4. Discussion
Treatment for chronic pain, including cLBP, is difﬁcult. Reports
for the effectiveness of available drugs, which may not have
considered the heterogeneity of cLBP, demonstrate at most modestimprovement in lessening the pain with minimal help in the
physical and emotional functioning [24]. Evidence indeed exists for
the effectiveness of NSAIDs and certain opioid drugs but the asso-
ciated side effects have signiﬁcant clinical consequences [20]. The
search for an effective pharmacological agent with little side effect
is therefore in need. Our study clearly shows that AGC can effec-
tively ameliorate cLBP resulting from degenerative vertebral dis-
eases. The pain-killing effect was evident after 2 weeks of
treatment (p < 0.0001 compared to placebo), a time point when a
decrease of 1.7 points in NRSwas achieved, in contrast to a decrease
of 0.9 in the placebo group (Table 1). In the time-to-event analysis
(Table 1), we included 23 patients in the AGC group and 8 patients
of the placebo group that stopped the trial early. We have also
calculated the total sample size of 459 patients (AGC n ¼ 347 and
placebo n ¼ 112) with a change in NRS pain score from baseline to
week 3, with a difference of 1.60 units (AGC group mean ¼ 2.76,
SD¼ 0.96; placebo groupmean¼1.16, SD¼ 0.91), which provides
>99% power to detect such a difference with a two-sample t test
and a two-sided type I error of 0.05. It was interesting to note that
treatment for an additional week further reduced the pain in-
tensity. Therefore, the primary efﬁcacy endpoint was achieved
irrespective of the data imputation method. Analyses for the sec-
ondary efﬁcacy endpoint demonstrated that 83.9% AGC-treated
patients had at least 30% reduction in the pain score at week 3,
whereas only 38.4% of placebo-treated patients had a similar
response (Table 2). Consistently, there were signiﬁcantly more pa-
tients in AGC-treated group having more than 50% reduction of the
pain intensity (54.5% vs. 8.04% in the placebo group; Table 2). The
NNT (a treatment-speciﬁc measure reliably describing the differ-
ence between a treatment and a control in achieving a particular
clinical outcome) for AGC treatment to achieve >30% reduction in
pain intensity was 2.2 and that to achieve >50% reduction was 2.15
(Table 2), indicating potent effects of AGC treatment. We have
further made stratiﬁcation and analyzed the effect of gender, age
and body mass index (BMI) over the primary efﬁcacy endpoint and
found that none of these factors affected the therapeutic effect of
AGC treatment (vs placebo; Appendix Table 1).
The further reduction of the pain intensity at week 3 of AGC
treatment is interesting. We do not have satisfactory explanations
at the moment because pharmacokinetic data of AGC are not
available. As a matter of fact, the studies on the pharmacokinetics
or pharmacodynamics would be hardly possible because AGC is a
biological mixture with unknown active ingredient(s). In spite of
this, the efﬁcacy of AGC to alleviate cLBP is established by this trial.
We have also performed a post-hoc analysis to match the placebo
(unexposed) patients to AGC (exposed) patients by age and sex in a
ratio of 1 to 1 (112:112) based on the logit of the propensity score
using a logistic regression model. Consistently, there was no dif-
ference in the personal characteristics and AGC treatment exhibited
signiﬁcant improvement compared to the placebo group at both
week 2 and 3 (Appendix Table 2).
Despite ~25e26% of patients reporting treatment-emergent
adverse events, which was not higher than placebo patients,
there was no evidence for a higher incidence of direct drug-related
side effects associated with AGC treatment (Table 3). AGC treatment
therefore appeared safe and well tolerated. This is unsurprising
because AGC has been clinically used in China for decades without
reported undesirable effects. Furthermore, the chronic toxicology
study of AGC in rats and dogs for continuous 3-month treatment
revealed nomajor side effects either (data not shown). In this sense,
AGC treatment is superior to the use of NSAIDs and opioids. Taking
intestinal function for an example, NSAIDs treatment causes a
higher relative risk of gastrointestinal diseases. [6] meanwhile,
constipation could happen in 15e90% patients receiving opioid
treatment and may occur within weeks of use [25e27]. In contrast,
Table 2
Summary of efﬁcacy parameters.
AGC Placebo Difference of least square means (SE;
95% CI)
P value RR or AHR
n ¼ 347 n ¼ 112
Change in numerical rating scale (per week) from baseline to week 3 0.92 (0.03) 0.38
(0.06)
0.63 (0.09; 0.80 to 0.45) <0.0001
Effect size (Cohen's f2)a e e 0.13
Patients with a 30% or 50% reduction in numerical rating scale from baseline to week 3
30% 291 (83.9%) 43
(38.4%)
e <0.0001 2.18 (1.94e2.46)b
50% 189 (54.5%) 9 (8.04%) e <0.0001 6.78 (4.94e9.31)c
NNT to achieve 30% reduction in pain at week 3 based on the numerical
rating scale (95% CI)
2.20 (1.83
e2.83)
e
NNT to achieve 50% reduction in pain at week 3 based on the numerical
rating scale (95% CI)
2.15 (1.89
e2.62)
e
Median time (days) to at least 30% decrease of the numerical rating scale from
baseline (95% CI)
14 (14e21) e 0.0004 0.50 (0.35e0.74)
Data are least square means (standard error (SE)) or n (%), unless otherwise indicated.
RR ¼ relative risk; AHR ¼ adjusted hazard ratio; NNT ¼ number needed to treat.
The tertiary efﬁcacy endpoint of time (week 2). For comparison between AGC and placebo treatment, the KaplaneMeier method was used to estimate event curves for each
group, and the log-rank test was used to test the homogeneity between event curves.
a Cohen's f2, a measure of local effect size, calculated using a multiple mixed repeated measures model. According to Cohen's (1988) guidelines, f2  0.02, f2  0.15, and
f2  0.35 represent small, medium, and large effect sizes, respectively.
b The unadjusted odds ratio was 8.34 (95% CI 5.18e13.42; p < 0.0001), and the adjusted odds ratio was 8.54 (5.27e13.86; p < 0.0001).
c The unadjusted odds ratio was 13.69 (95% CI 6.71e27.94; p < 0.0001), and the adjusted odds ratio was 14.08 (6.85e28.91; p < 0.0001).
Fig. 2. The mean change in the numerical rating scale from baseline by week of
treatment. Data are the mean change from baseline in average weekly numerical rating
scale per week of treatment using the mixed model repeated measures analysis. AGC
vs. Placebo (*P < 0.0001 at week 2 and 3).
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ated with AGC treatment (Table 3). AGC treatment did not lead to
changes in the blood cell counts or important biochemical pa-
rameters (for liver and renal functions), or abnormal EKG readings
either (Table 4). Intriguingly, however, more placebo-treated pa-
tients had lower-than-normal RBC counts and hemoglobin (Hb) at
the end of the trial, as well as higher-than-normal levels of blood
urea nitrogen (BUN; Table 4). The reason is unclear and we noticed
that those having low RBC and Hb were all post-menopause
women and those having high BUN were all male (in both AGC
and placebo groups), and none of them had abnormal blood cell
counts or BUN levels prior to treatment (data not shown). Whether
or not this implies that AGC may contain other molecules with
additional biological functions deserves further investigation. In
any case, no serious side effects could be attributable to AGC
treatment.
Early stopping of a clinical trial for evidence of beneﬁt has been
widely debated in the medical literature [28e31]. The treatment
period of this study was initially designed to be 4 weeks but the
trial was stopped one week earlier because the results at week 2and 3 were consistent with the pre-speciﬁed stopping guideline.
Furthermore, the level of statistical signiﬁcance observed at week 2
and 3 minimized the concerns that the ﬁndings could be reversed
or simply reﬂected the play of chance. Moreover, aftermatching the
placebo patients to AGC patients by age and sex in a ratio of 1:1
using a logistic regression model, the conclusion still stood. Finally,
the results were consistent with previous trials of AGC, despite
being in a small scale, for treating other types of pain [21,22]. An
additional potential limitation of this trial, as seen in most trials for
pain evaluation, is the use of the NRS to measure the pain severity
which, similar to the visual analog score (VAS), evaluates only a
particular component of the pain intensity and therefore does not
capture the complexity and idiosyncratic nature of the pain expe-
rience from symptom ﬂuctuations. Nevertheless, such potential
imprecision could have been disregarded by the remarkable dif-
ference in the NRS reduction between the exposed and non-
exposed groups at the end of week 2 and 3.
We have compared the effects of AGCwith the results from trials
studying the effects of other drugs, although the treatment period
between different trials varied and the parameters for determining
efﬁcacy might differ. We used the I2 statistics to assess the het-
erogeneity between trials. The I2 index has been proposed to
quantify the degree of heterogeneity in a meta-analysis [32], and
values higher than 50%were deﬁned to identify high heterogeneity.
A meta-analysis with I2 ¼ 0 means that all variability in effect size
estimates is due to sampling error within studies (homogeneity
hypothesis). Furthermore, percentages of around 25% (I2¼ 25), 50%
(I2¼ 50), and 75% (I2¼ 75) are regarded to represent low, medium,
and high heterogeneity, respectively. In the meta-analysis, we
calculated weightedmean differences and 95% conﬁdence intervals
and used the random effects model to pool estimates for each
analysis obtained with Comprehensive Meta-Analysis version
2.2.048 (Englewood, NJ, 011). The comparison clearly revealed that
in terms of the magnitude in pain relief (vs. placebo), AGC is more
effective than paracetamol, regardless for immediate (<2 weeks) or
short term efﬁcacy (>2weeks but< 3months); furthermore, for the
short term efﬁcacy, AGC (3 weeks vs. placebo; mean
difference 1.61, 95% CI 1.96 to 1.26) is equivalent to oxycodone
(12 weeks vs. placebo; mean difference 1.20, 95% CI 1.89
to 0.51) (Table 5 & Appendix Table 3). In terms of the change in
Fig. 3. The KaplaneMeier plot for the tertiary efﬁcacy endpoint of time vs pain intensity from the baseline. The number of patients in each group at indicated time points is given
along the time axis.
Table 3
Total and speciﬁc treatment-related adverse events.
AGC Placebo P
N ¼ 324 N ¼ 104
Total treatment-emergent adverse events, n 85 26
Patients reporting one or more treatment emergent adverse events, n (%) 47 (14.5%) 16 (16.3%) 0.8738
Treatment-emergent adverse events by preferred term and organ system, n (% of total patients)
Major events
Acute bronchitis/pneumonia 17 (5.2%) 6 (5.8%) 0.5936
Minor adverse events 68 (21%) 20 (19.2%) 0.7810
Gastrointestinal system
Stomachache 12 (3.7%) 4 (3.8%) 1.0000
Nausea 11 (3.4%) 3 (2.9%) 1.0000
Abdominal discomfort 10 (3.1%) 3 (2.9%) 1.0000
Nervous system
Headache 9 (2.8%) 3 (2.9%) 1.0000
Skin
Itching 19 (5.9%) 6 (5.8%) 1.0000
Dermatitis 7 (2.2%) 1 (1%) 0.6859
Note: Data of categorical variables was analyzed by Fisher's exact test to make comparisons between groups.
Table 4
Percentage of patients with out-of-range blood cell count and biochemistry at the end of the trial (week 3).
Clinical and biochemistry parameters AGC Placebo P value*
n ¼ 324 (%) n ¼ 104 (%)
Blood cell count
Red blood cell (RBC) 12 (3.7) 10 (9.6) 0.018#
White blood cell (WBC) 16 (4.9) 4 (3.8) 0.793
Platelet 11 (3.4) 5 (4.8) 0.553
Serum biochemistry
Hemoglobin (Hb) 12 (3.7) 12 (11.5) 0.003#
Bilirubin (total) 20 (6.2) 6 (5.8) 0.881
Alanine transaminase (GPT) 13 (4.0) 3 (2.9) 0.771
Aspartate transaminase (GOT) 5 (1.5) 4 (3.8) 0.230
Blood urea nitrogen (BUN) 13 (4.0) 10 (9.6) 0.028#
Creatinine 8 (2.5) 2 (1.9) 1.000
Electrocardiography (abnormal readings)a 39 (12.0) 16 (15.4) 0.334
Note: *Categorical variables were analyzed by chi-square test or Fisher's exact test to make comparisons among groups, as appropriate.
#p < 0.05.
a Including arrhythmias, prolonged PR intervals, ST depression, or T wave inversion.
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Table 5
Mean differences of AGC, Paracetamol, NSAIDs, Oxycodone, Buprenorphine and
Duloxetine for the treatment of chronic nonspeciﬁc low back pain according to the
reduction of the pain intensity vs. placebo or the change in the pain intensity vs.
baselinea.
Mean difference (95% CI)
Parameter 1. Reduction of the pain intensity (vs. placebo)
Immediate term
AGC (2 weeks) 0.77 (1.07, 0.48)
Paracetamol (2 weeks) 0.10 (0.12, 0.32)
(1 trial)
Short term 1.61 (1.96, 1.26)
AGC (3 weeks)
Paracetamol (4 weeks) 0.10 (0.19, 0.39)
(1 trial)
Oxycodone (12 weeks) 1.20 (1.89, 0.51)
(1 trial)
Parameter 2. Change in the pain intensity (vs. baseline)
Short term
AGC (3 weeks) 1.60 (1.80, 1.40)
NSAIDs (4e12 weeks)a 1.20 (1.50, 0.91)
(4 trials, Mata-analysis I2 ¼ 0.0%; P < 0.0001)
Buprenorphine (8e24 weeks)a 0.75 (1.18, 0.31)
(2 trials, Mata-analysis I2 ¼ 0.0%; P ¼ 0.0009)
Oxycodone (12 weeks) 0.84 (1.19, 0.50)
(2 trials, Mata-analysis I2 ¼ 0.0%; P < 0.0001)
Duloxetine (7e13 weeks) 0.94 (1.04, 0.35)
(2 trials, Mata-analysis I2 ¼ 0.0%; P ¼ 0.0001)
Note: Immediate term¼ follow-up2 weeks; short term¼ follow-up >2 weeks but
3 months; CI ¼ conﬁdence interval.
a Clinic trials, see Appendix Table 3.
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mean difference 1.60, 95% CI 1.80 to 1.40) is equivalent to that
of NSAIDs (12 weeks vs. baseline; mean difference 12.04, 95%
CI 15.00 to 9.08), whereas AGC is more efﬁcacious than opioid
drugs, including Buprenorphine, Oxycodone and Duloxetine [mean
difference 1.60, 95% CI 1.80 to 1.40 for AGC (3 weeks); mean
difference 7.46, 95% CI 11.80 to 3.11 for Buprenorphine (24
weeks); mean difference 0.84, 95% CI 1.19 to 0.50 for Oxyco-
done (12 weeks), and mean difference0.94, 95% CI1.04 to0.35
for Duloxetine (13 weeks)] (Table 5 & Appendix Table 3). Collec-
tively, AGC exhibits potent pain-killing capacity against cLBP and
the effect is comparable to or superior to most of existing phar-
macological agents, at least for the immediate and short terms.
In summary, the extracts of V. variola-infected rabbit skin
(Analgecine, AGC) efﬁcaciously ameliorate the chronic low back pain
caused by degenerative vertebral disorders and, more importantly,
it causes little side effect. Given its potency and safety, AGC can be
considered in the future clinical practice as the ﬁrst line treatment
for cLBP, not only for the sake of patient beneﬁts but also for
reducing the prescription of opioids and the resultant drug misuse
or abuse. Undoubtedly, AGC contains molecule(s) that possess
analgesic properties, and it is likely to contain additional molecules
or compounds that display other biological functions. AGC therefore
represents a novel source of animal-derived products deserving
investigation for drug discovery. This study also warrants the
identiﬁcation of the active component(s) in AGC contributing to the
power pain-killing effect.Acknowledgments
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